Singapore markets closed

Wave Life Sciences Ltd. (WVE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.17+0.13 (+2.15%)
At close: 04:00PM EDT
6.05 -0.12 (-1.94%)
After hours: 06:02PM EDT

Wave Life Sciences Ltd.

Marina One East Tower
7 Straits View No.12-00
Singapore 018936
Singapore
65 6236 3388
https://www.wavelifesciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees266

Key executives

NameTitlePayExercisedYear born
Dr. Paul B. Bolno M.B.A., M.D.President, CEO & Director1.1MN/A1974
Mr. Kyle B. Moran CFACFO & Principal Accounting Officer677.87kN/A1971
Dr. Chandra Vargeese Ph.D.Chief Technology Officer710.05kN/A1961
Kate RauschHead of Investor RelationsN/AN/AN/A
Ms. Linda Rockett J.D.Senior VP & General CounselN/AN/AN/A
Dr. Christopher Francis Ph.D.Senior VP of Corporate Development & Head of Emerging Areas493.13k4.75M1978
Ms. Daryn LewisSenior VP & Head of Human ResourcesN/AN/AN/A
Dr. Sridhar Vaddeboina Ph.D.Senior Vice President of Chemistry, Manufacturing & ControlsN/AN/AN/A
Ms. Anne-Marie Li-Kwai-CheungChief Development OfficerN/AN/AN/A
Dr. Hsiu-Chiung Yang Ph.D.Senior Vice President of Translational MedicineN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Corporate governance

Wave Life Sciences Ltd.’s ISS governance QualityScore as of 1 March 2024 is 4. The pillar scores are Audit: 7; Board: 2; Shareholder rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.